Publications

Nature

Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.

01-09-2022

Molecular cell

Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.

18-11-2021

The Journal of experimental medicine

MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.

06-11-2023

Cell reports

Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors.

30-05-2023

Cell reports

Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer.

25-04-2023

Archives of gynecology and obstetrics

Effects of chemotherapy on ovaries of pregnant mice.

01-04-2023

Cell reports. Medicine

Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer.

15-11-2022

Nature communications

MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling.

02-11-2022

Cancer research communications

Loss of the volume-regulated anion channel components LRRC8A and LRRC8D limits platinum drug efficacy.

26-10-2022

PloS one

Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity.

07-09-2022

Nature

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.

01-08-2022

Nucleic acids research

Division of labor within the DNA damage tolerance system reveals non-epistatic and clinically actionable targets for precision cancer medicine.

22-07-2022

Breast cancer research : BCR

Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer.

17-06-2022

BMC medical research methodology

Developing a dynamic simulation model to support the nationwide implementation of whole genome sequencing in lung cancer.

27-03-2022

Cancer research

A Microfluidic Cancer-on-Chip Platform Predicts Drug Response Using Organotypic Tumor Slice Culture.

01-02-2022

Cancer research

A BRCA1 Coiled-Coil Domain Variant Disrupting PALB2 Interaction Promotes the Development of Mammary Tumors and Confers a Targetable Defect in Homologous Recombination Repair.

15-12-2021

Cell reports

Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumors.

24-08-2021

Cell stem cell

Patient-derived organoids model cervical tissue dynamics and viral oncogenesis in cervical cancer.

05-08-2021

Expert review of pharmacoeconomics & outcomes research

Early technology assessment of using whole genome sequencing in personalized oncology.

01-06-2021

BMC cancer

Whole genome sequencing in oncology: using scenario drafting to explore future developments.

01-05-2021

The Journal of molecular diagnostics : JMD

Real-World Utilization of Biomarker Testing for Patients with Advanced Non-Small Cell Lung Cancer in a Tertiary Referral Center and Referring Hospitals.

01-04-2021

Cell reports

Functional Radiogenetic Profiling Implicates ERCC6L2 in Non-homologous End Joining.

25-08-2020

The EMBO journal

In situ CRISPR-Cas9 base editing for the development of genetically engineered mouse models of breast cancer.

02-03-2020

The EMBO journal

SLC1A3 contributes to L-asparaginase resistance in solid tumors.

04-10-2019

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Micro cone beam computed tomography for sensitive assessment of radiation-induced late lung toxicity in preclinical models.

01-09-2019

Lung cancer (Amsterdam, Netherlands)

Variation in the time to treatment for stage III and IV non-small cell lung cancer patients for hospitals in the Netherlands.

01-08-2019

Clinical cancer research : an official journal of the American Association for Cancer Research

EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy.

15-07-2019

Nature medicine

An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.

01-05-2019

Molecular cancer therapeutics

Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin.

01-04-2019

The EMBO journal

Long-term expanding human airway organoids for disease modeling.

15-02-2019

Cancer research

Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.

01-02-2019

Nature communications

Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer.

23-01-2019

The Journal of pathology

BRCA1-associated mammary tumorigenesis is dependent on estrogen rather than progesterone signaling.

01-09-2018

Cancer cell

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.

11-06-2018

Cell reports

The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells.

15-05-2018

Oncotarget

Precision cancer therapy: profiting from tumor specific defects in the DNA damage tolerance system.

10-04-2018

Cancer discovery

E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.

01-04-2018

Nature methods

BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance.

01-02-2018

Cell

A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity.

11-01-2018

Nature cell biology

EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation.

01-11-2017

European urology

A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.

01-06-2017

The Journal of pathology

Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.

01-03-2017

Genes & development

Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland.

15-06-2016

DNA repair

Effects of compound heterozygosity at the Xpd locus on cancer and ageing in mouse models.

01-11-2012

The Journal of pathology

Fancf-deficient mice are prone to develop ovarian tumours.

01-01-2012

The Journal of experimental medicine

Domains of the TCR beta-chain required for early thymocyte development.

01-11-1996

Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.

Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.

MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.

Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors.

Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer.

Effects of chemotherapy on ovaries of pregnant mice.

Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer.

MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling.

Loss of the volume-regulated anion channel components LRRC8A and LRRC8D limits platinum drug efficacy.

Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity.

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.

Division of labor within the DNA damage tolerance system reveals non-epistatic and clinically actionable targets for precision cancer medicine.

Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer.

Developing a dynamic simulation model to support the nationwide implementation of whole genome sequencing in lung cancer.

A Microfluidic Cancer-on-Chip Platform Predicts Drug Response Using Organotypic Tumor Slice Culture.

A BRCA1 Coiled-Coil Domain Variant Disrupting PALB2 Interaction Promotes the Development of Mammary Tumors and Confers a Targetable Defect in Homologous Recombination Repair.

Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumors.

Patient-derived organoids model cervical tissue dynamics and viral oncogenesis in cervical cancer.

Early technology assessment of using whole genome sequencing in personalized oncology.

Whole genome sequencing in oncology: using scenario drafting to explore future developments.

Real-World Utilization of Biomarker Testing for Patients with Advanced Non-Small Cell Lung Cancer in a Tertiary Referral Center and Referring Hospitals.

Functional Radiogenetic Profiling Implicates ERCC6L2 in Non-homologous End Joining.

In situ CRISPR-Cas9 base editing for the development of genetically engineered mouse models of breast cancer.

SLC1A3 contributes to L-asparaginase resistance in solid tumors.

Micro cone beam computed tomography for sensitive assessment of radiation-induced late lung toxicity in preclinical models.

Variation in the time to treatment for stage III and IV non-small cell lung cancer patients for hospitals in the Netherlands.

EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy.

An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.

Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin.

Long-term expanding human airway organoids for disease modeling.

Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.

Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer.

BRCA1-associated mammary tumorigenesis is dependent on estrogen rather than progesterone signaling.

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.

The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells.

Precision cancer therapy: profiting from tumor specific defects in the DNA damage tolerance system.

E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.

BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance.

A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity.

EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation.

A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.

Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.

Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland.

Effects of compound heterozygosity at the Xpd locus on cancer and ageing in mouse models.

Fancf-deficient mice are prone to develop ovarian tumours.

Domains of the TCR beta-chain required for early thymocyte development.

This site uses cookies